Preoperative Bleeding Risk Assessment via Fibrin Monomer and aPTT

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods, such as aPTT and PT tests, are poorly suited for predicting intraoperative bleeding risk, as they are unreliable and fail to accurately identify coagulation factor levels or bleeding tendencies.

Innovation Solution

Combining fibrin monomer (FM) determination with activated partial thromboplastin time (aPTT) in a patient sample to improve diagnostic sensitivity and specificity for preoperative screening of intraoperative bleeding risk.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If aPTT and PT tests are used to predict intraoperative bleeding risk, then the tests are commonly performed, but they are unreliable and fail to accurately identify coagulation factor levels or bleeding tendencies

Engineering Contradiction:

Improvepredictive accuracy of bleeding riskVSAvoidaccuracy of coagulation factor level detection

Core Design Contradiction:

ReliabilityVSMeasurement precision

Solution Approach 1:

The patent combines aPTT and fibrin monomer determination into a composite assessment method. This merging of two different measurement approaches (aPTT for coagulation time and fibrin monomer for coagulation activation) creates a more reliable predictive model for intraoperative bleeding risk, overcoming the limitations of using either test alone.

Inventive Principle:

Principle #5Merging (Combining)

Solution Approach 2:

The patent introduces fibrin monomer as an intermediary marker that bridges the gap between coagulation activation and bleeding risk prediction. Fibrin monomer serves as a mediator that directly reflects coagulation activation status, providing more accurate predictive value than aPTT alone while maintaining the clinical utility of the aPTT test.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Measurement precision

If fibrin monomer determination is used for preoperative screening, then diagnostic potential is good, but predictive quality can be improved by combining with aPTT

Engineering Contradiction:

Improvediagnostic sensitivityVSAvoidnumber of examination methods

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent merges fibrin monomer determination with aPTT testing to create a composite diagnostic approach. This combination increases diagnostic sensitivity for identifying patients at risk of intraoperative bleeding while maintaining clinical feasibility through the use of standard laboratory infrastructure for both tests.

Inventive Principle:

Principle #5Merging (Combining)

3Ease of operation

If aPTT is used alone to stratify bleeding risk, then the test is simple, but it cannot reliably detect coagulation activation or predict bleeding tendency

Engineering Contradiction:

Improvesimplicity of testingVSAvoidpredictive value for bleeding tendency

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent introduces fibrin monomer as an intermediary marker that complements aPTT. While aPTT measures coagulation time, fibrin monomer directly indicates coagulation activation status. This intermediary marker provides the additional predictive information needed to reliably detect bleeding tendency without significantly complicating the testing procedure.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentEP2310864B1Method for the preoperative determination of the intraoperative risk of bleeding of a patient

Publication Date: 2014.01.29 ZENT FUR LABORMEDIZIN

Figure 1

AI summary

In order to determine the intraoperative risk of bleeding preoperatively, both the content of fibrin monomer (FM) and the partial thromboplastin time (PTT) are determined in a blood or plasma sample.